Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation

• Status: Active, not recruiting
• Trial end date: 2021-12-01

Summary

Phase II trial to determine the efficacy of Dose Adjusted-EPOCH-Rituximab regimen in children and adolescent with primary mediastinal large B cell lymphoma in terms of event free survival.

• Phase: Phase 2

Details

• Lead Sponsor: Children's Oncology Group; Gustave Roussy, Cancer Campus, Grand Paris
• Collaborators: Children's Oncology Group; National Cancer Institute (NCI)
• Treatments: Calcium, Dietary; Cortisol succinate; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Hydrocortisone; Hydrocortisone 17-butyrate 21-propionate; Hydrocortisone acetate; Leucovorin; Levoleucovorin; Liposomal doxorubicin; Methotrexate; Methylprednisolone; Methylprednisolone acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate; Prednisone; Rituximab; Vincristine